PASG
Price:
$0.751
Market Cap:
$46.39M
Passage Bio, Inc., a genetic medicines company, develops transformative therapies for central nervous system diseases. It develops PBGM01, which utilizes a proprietary, AAVhu68 capsid to deliver to the brain and peripheral tissues a functional GLB1 gene encoding lysosomal acid beta-galactosidase for infantile GM1; PBFT02, which utilizes an AAV1 capsid to deliver to the brain a functional granulin (GRN) and gene encoding progranulin (PGRN) for the treatment of FTD-GRN; and PBKR03, which utilizes a proprietary, AAVhu68 capsid to deliver to the brain and peripheral tissues a functional GALC gene encoding the hydrolytic enzyme galactosylceramidase for infantile Krabbe disease. The company also d...[Read more]
Industry
Biotechnology
IPO Date
2020-02-28
Stock Exchange
NASDAQ
Ticker
PASG
According to Passage Bio, Inc.’s latest financial reports and current stock price. The company's current ROE is -72.53%. This represents a change of 285.55% compared to the average of -18.81% of the last 4 quarters.
The mean historical ROE of Passage Bio, Inc. over the last ten years is -30.48%. The current -72.53% ROE has changed 137.99% with respect to the historical average. Over the past ten years (40 quarters), PASG's ROE was at its highest in in the June 2019 quarter at 0%. The ROE was at its lowest in in the September 2024 quarter at -26.60%.
Average
-30.48%
Median
-48.39%
Minimum
-91.71%
Maximum
104.90%
Discovering the peaks and valleys of Passage Bio, Inc. ROE, unveiling quarterly and yearly fluctuations to gain insights into the company’s financial performance and market dynamics, offering valuable data for investors and analysts alike.
Maximum Annual Increase = 63.85%
Maximum Annual ROE = 104.90%
Minimum Annual Increase = -129.84%
Minimum Annual ROE = -91.71%
Year | ROE | Change |
---|---|---|
2023 | -91.71% | 34.95% |
2022 | -67.96% | 13.09% |
2021 | -60.10% | 63.85% |
2020 | -36.68% | 17.17% |
2019 | -31.30% | -129.84% |
The current ROE of Passage Bio, Inc. (PASG) is greater than its 3-year, greater than its 5-year, and greater than its 10-year historical averages
3-year avg
-73.26%
5-year avg
-57.55%
10-year avg
-30.48%
Passage Bio, Inc.’s ROE is greater than Black Diamond Therapeutics, Inc. (-68.08%), greater than Revolution Medicines, Inc. (-33.67%), greater than Homology Medicines, Inc. (-100.91%), greater than Stoke Therapeutics, Inc. (-54.45%), greater than Cabaletta Bio, Inc. (-50.10%),
Company | ROE | Market cap |
---|---|---|
-68.08% | $139.77M | |
-33.67% | $9.86B | |
-100.91% | $3.02M | |
-54.45% | $623.42M | |
-50.10% | $118.28M |
One of the best ways to find valuable stocks to invest in is to build a custom made screener in your Excel or Google Sheets spreadsheet. This allows you to compare thousands of companies like Passage Bio, Inc. using the financials and key metrics that matter to you in a single view.
The easiest way to set this up is to use the Wisesheets add-on and set your spreadsheet like this:
Covering all these metrics from financial, data, dividend data, key metrics and more you can get all the data you want for over 50+ exchanges worldwide.
Get your free trial here.
The easiest way to analyze a company like Passage Bio, Inc. or any others is to create a spreadsheet model that automatically retrieves all of the stock data you need.
Using Wisesheets you can set up a spreadsheet model like this with simple spreadsheet formulas. If you change the ticker you can get all of the data automatically updated for you.
Whether you need live data, historical price data, financials, dividend data, key metrics, analyst estimates, or anything else...Wisesheets has you covered.
What is the ROE?
How can you use the ROE?
What is Passage Bio, Inc.'s ROE?
How is the ROE calculated for Passage Bio, Inc. (PASG)?
What is the highest ROE for Passage Bio, Inc. (PASG)?
What is the 3-year average ROE for Passage Bio, Inc. (PASG)?
What is the 5-year average ROE for Passage Bio, Inc. (PASG)?
How does the current ROE for Passage Bio, Inc. (PASG) compare to its historical average?